Live·Open questions in longevity research
All news
Therapeutics

India’s PopVax releases tumor data, code, and a personalized mRNA vaccine design for a 34-year-old pancreatic cancer patient and seeks expert review before manufacturing

12 November 2026· 261112010

India’s PopVax releases tumor data, code, and a personalized mRNA vaccine design for a 34-year-old pancreatic cancer patient and seeks expert review before manufacturing

On November 11, PopVax founder Soham Sankaran announced that the company is openly developing a vaccine for Yashdeep Bindal, who has metastatic cancer, with his consent. His tumor DNA and RNA sequencing data, blood-cell DNA sequencing data, clinical reports, code, and lead vaccine design are available on GitHub. The company plans to manufacture the vaccine at its PopVax RNA Foundry facility.

At this facility, PopVax launched a service for producing personalized cancer vaccines on October 30. The company expects most projects to cost around 300 thousand dollars and take 8–10 weeks. It explains its rationale as follows:

“For many cancers, regulatory approvals may come too late for many patients living with these diseases today.”

The vaccine consists of a single mRNA molecule designed to instruct Yashdeep’s cells to make a protein of 724 amino acids, composed mainly of 24 blocks of 25 amino acids each, joined by short linkers. Cells break their proteins into fragments and display them on their surface in HLA molecules, which hold the fragments in place. T cells inspect these fragments and attack cells displaying material they recognize as foreign. The vaccine protein is intended to undergo the same process. Its blocks were selected to yield fragments present in the tumor but absent from healthy cells, so that T cells can learn to recognize the tumor.

After surgical removal of melanoma, the personalized mRNA therapy intismeran, added to immunotherapy, reduced the risk of recurrence or death by 42% in a phase III trial. Only some vaccine targets elicit a response, however. In a phase I trial, a personalized vaccine from BioNTech and Genentech was administered after pancreatic cancer surgery; 25 of the 230 targets delivered elicited a strong T-cell response. In an April essay, Sankaran wrote about these vaccines:

“These vaccines act like revolvers loaded with at most one live round, with the vast majority of shots firing blanks.”

Twelve of the 24 blocks come from tumor mutations whose altered proteins appear foreign; five come from unusual joins made when a gene’s RNA copy is spliced, which are expected to produce fragments absent from normal proteins; five come from cancer-testis proteins, whose genes are normally active only in the testes but have become active in Yashdeep’s tumor; and two come from the fusion gene CDH1::NRG1, formed when a rare genetic alteration joined halves of two genes in the tumor. Of 342 protein-altering mutations, 12 were retained: they were detected in the tumor RNA, and software predicted that the altered fragments would bind to Yashdeep’s HLA molecules.

The first design, based solely on tumor DNA and RNA, included 17 mutations. Comparison with blood-cell DNA showed that seven of them were also present in healthy cells. Those seven were removed and two others added, bringing the total to 12.

Less than an hour after the announcement, the first external review appeared. A user’s AI agent submitted it while the user was away, and another contributor reproduced the calculation. The review compared the blocks against a catalog of human proteins. In four of the five splice-derived blocks, the fragments spanning the splice junction were absent from normal proteins, and within each block, all of those fragments carried the same additional amino acid substitution. Without that substitution, the fragments matched normal proteins. The review therefore concluded that both the substitution itself and its presence on the same tumor RNA molecules as the splice junction needed confirmation. Even before the review, PopVax had described the substitution in two blocks as a weak point. That same day, the company documented the substitutions in all four blocks and added a script that reproduces the comparison. Anyone can propose a design, provided they include the rationale and code.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#personalized-mrna-vaccine#pancreatic-cancer#neoantigens#hla#open-source